approval by FDA for its first anti-PD-L1 cancer immunotherapy namely Tecentriq ( atezolizumab ), thereby expanding its product portfolio .
Purchase a copy of this report @ http :// www . orbisresearch . com / contact / purchase / 216076 . Key benefits
The drivers , restraints , and opportunities in the global cancer biomarkers market are expected to help in understanding the market behavior better . The market estimations are a result of high-end analysis of the key market segments for the period of 2014 – 2022 Projections in the report are made by analyzing the current market trends and future market potential for the forecast period in terms of value . The analysis helps in understanding the strategies adopted by various companies for the growth of the global cancer biomarkers market . Country level analysis has been done to provide micro market sizing of cancer biomarkers in different regions Porter ' s five forces model gives an in-depth analysis of bargaining power of buyers and suppliers , threats of new entrants & substitutes , and competition amongst the key market players .
For more information contact sales @ orbisresearch . com
Some Point ’ s from Table of Content :
Chapter 1 Introduction 1.1 Report description 1.2 Key benefits 1.3 Key market segments 1.4 Research methodology 1.4.1 Secondary research 1.4.2 Primary research 1.4.3 Analyst tools and models
Chapter 2 Executive Summary 2.1 CXO perspective
Chapter 3 Market Overview 3.1 Market definition and scope 3.2 Biomarker diagnosis vs . conventional diagnosis 3.3 Key findings 3.3.1 Drivers 3.3.1.1 Rise in incidence and prevalence of various cancer types 3.3.1.2 Growth in importance of biological and targeted drug therapies
3